Kynamro

Active Ingredient(s): Mipomersen Sodium
FDA Approved: * January 29, 2013
Pharm Company: * GENZYME CORP
Category: Cholesterol

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Kynamro Overview

Mipomersen (INN; trade name Kynamro) is used to treat homozygous familial hypercholesterolemia and is administered by subcutaneous injection. There is a serious risk of liver damage from this drug and it can only be prescribed in the context of a risk management plan. Contents 1 Indications 1.1 Pregnancy and lactation 2 Contraindications 3 Adverse effects 4 Interactions 5 Pharmacology 5.1 Mechanism of action 5.2 Pharmacokinetics 6 Chemistry 7 History 8 References Indications K...

Read more Kynamro Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Mipomersen

Recent Kynamro Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Mipomersen Sodium
  • Injection: 200mg/ml
  • Solution: 200mg/ml (200mg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Kynamro: (3 results)

Sorted by National Drug Code
  • 58468-0190 Kynamro 200 mg/ml Subcutaneous Injection, Solution by Genzyme Corporation
  • 58468-0191 Kynamro 200 mg/ml Subcutaneous Injection, Solution by Genzyme Corporation
  • 70688-0502 Kynamro 200 mg/ml Subcutaneous Injection, Solution by Kastle Therapeutics LLC

Other drugs which contain Mipomersen Sodium or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 18 January 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA